Clicky

Altimmune, Inc.(ALT)

Description: Altimmune,Inc., formerly Pharmathene, Inc., is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.


Keywords: Medicine Vaccines Phosphates Manufacturing Process Nerve Manufacturing Processes Biological Warfare Biodefense Choline Reversal Anthrax Athene Chemical Warfare Cholinesterase Anthrax Vaccines

Home Page: altimmune.com

ALT Technical Analysis

910 Clopper Road
Gaithersburg, MD 20878
United States
Phone: 240 654 1450


Officers

Name Title
Dr. Vipin K. Garg Ph.D. Pres, CEO & Director
Mr. Richard I. Eisenstadt M.B.A. Chief Financial Officer
Dr. M. Scot Roberts Ph.D. Chief Scientific Officer
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS Chief Medical Officer
Mr. Bertrand Georges Ph.D. Chief Technology Officer
Mr. Tony Blandin B.S. VP of Quality & Compliance Management
Mr. José Ochoa Chief Bus. Officer
Mr. Kent A. Tapper BSEE Corp. Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.5847
Price-to-Sales TTM: 162.9822
IPO Date: 2005-10-06
Fiscal Year End: December
Full Time Employees: 47
Back to stocks